GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » ROC %

SINTX Technologies (SINTX Technologies) ROC % : -114.46% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. SINTX Technologies's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was -114.46%.

As of today (2024-06-06), SINTX Technologies's WACC % is 4.38%. SINTX Technologies's ROC % is -122.84% (calculated using TTM income statement data). SINTX Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.


SINTX Technologies ROC % Historical Data

The historical data trend for SINTX Technologies's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SINTX Technologies ROC % Chart

SINTX Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -113.28 -185.08 -165.92 -99.61 -105.64

SINTX Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.09 -129.43 -151.66 -109.75 -114.46

SINTX Technologies ROC % Calculation

SINTX Technologies's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-13.358 * ( 1 - 0% )/( (14.59 + 10.699)/ 2 )
=-13.358/12.6445
=-105.64 %

where

SINTX Technologies's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-12.788 * ( 1 - 0% )/( (10.699 + 11.646)/ 2 )
=-12.788/11.1725
=-114.46 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SINTX Technologies  (NAS:SINT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, SINTX Technologies's WACC % is 4.38%. SINTX Technologies's ROC % is -122.84% (calculated using TTM income statement data). SINTX Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


SINTX Technologies ROC % Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


SINTX Technologies (SINTX Technologies) Business Description

Traded in Other Exchanges
Address
1885 West 2100 South, Salt Lake City, UT, USA, 84119
SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty.
Executives
David W. Truetzel director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien officer: Chief Operating Officer 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi officer: VP Finance C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin officer: Vice President, Finance C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros officer: See Remarks C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke 10 percent owner C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes director, officer: Chief Fnancial Officer
Vytas Rupinskas officer: SVP, Marketing C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson director, officer: President and CEO C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham officer: SVP, Global Sales C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield officer: Chief Commercial Officer C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link director 509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis officer: Chief Operating Officer 9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White director C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119